X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ISEE

Closed

Iveric Bio Inc

39.95
+0.15 (+0.38%)
Last Update: 11 Jul 2023 16:30:00
Yesterday: 39.8
Day's Range: 39.95 - 39.95
Send
When Written:
 
26.49
IVERIC bio Inc. is a biopharmaceutical company that is focused on the discovery and development of innovative therapies for the treatment of ophthalmic diseases. The company's pipeline includes drugs for the treatment of age-related macular degeneration, diabetic macular edema, and other retinal diseases.

The company was founded in 2017 as a spin-off from Ophthotech Corporation, and is headquartered in New York City. IVERIC bio's lead drug candidate is Zimura, a complement C5 inhibitor that is being developed for the treatment of geographic atrophy, a leading cause of blindness in the elderly.

In addition to Zimura, IVERIC bio is also developing a gene therapy for the treatment of Best disease, an inherited retinal disease that causes progressive vision loss. The company's gene therapy platform is based on adeno-associated virus (AAV) vectors, which are designed to deliver therapeutic genes to the retina.

Overall, IVERIC bio is focused on developing innovative therapies that can improve the lives of patients with ophthalmic diseases, and is committed to advancing the field of ophthalmology through cutting-edge research and development.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X